ITGA4 and neoplasm: These findings suggest that ITGA4 may be a valuable biomarker for predicting tumor response to immunotherapy, highlighting the potential advantages of screening patients with abnormal ITGA4 expression for personalized immune checkpoint inhibitor (ICI) treatment.